These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 10216565)

  • 1. Efficacy of two dose measles vaccination in a community setting.
    Phadke MA; Bhargava I; Dhaigude P; Bagade A; Biniwale MA; Kurlekar SU
    Indian Pediatr; 1998 Aug; 35(8):723-5. PubMed ID: 10216565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Need for measles revaccination.
    John TJ
    Indian Pediatr; 1998 Aug; 35(8):789-91. PubMed ID: 10216577
    [No Abstract]   [Full Text] [Related]  

  • 3. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
    Gonçalves G; Tavares F; de Andrade HR
    Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 5. Catch-up immunization programs will eliminate measles threat for most schoolchildren.
    Rafuse J
    CMAJ; 1996 May; 154(10):1567-8. PubMed ID: 8625011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Does a modified vaccination schedule protect better against measles?].
    van 't Spijker C; Rümke HC
    Ned Tijdschr Geneeskd; 1994 Nov; 138(48):2400-5. PubMed ID: 7990988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for using MMR vaccine in children allergic to eggs.
    Khakoo GA; Lack G
    BMJ; 2000 Apr; 320(7239):929-32. PubMed ID: 10787255
    [No Abstract]   [Full Text] [Related]  

  • 11. [Vaccination of children in 1999].
    Levy J
    Rev Med Brux; 1999 Sep; 20(4):A317-20. PubMed ID: 10523915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vaccination status and implementation of recommendations for vaccination with special reference to measles-mumps-rubella vaccination. 1995 program for school entrance].
    Ziemer B; Blank K; Hennig R
    Gesundheitswesen; 1998 May; 60(5):297-300. PubMed ID: 9676011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measles vaccination: revised recommendations for immunization.
    Reece SM
    Nurse Pract; 1990 Dec; 15(12):19-20, 23-4. PubMed ID: 2284058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroconversion after measles vaccination at nine and fifteen months of age.
    Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
    Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A second dose of MMR vaccine for children in the United Kingdom.
    Commun Dis Rep CDR Wkly; 1996 Jul; 6(30):259. PubMed ID: 8755703
    [No Abstract]   [Full Text] [Related]  

  • 16. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 17. MMR immunisation coverage in Christchurch. Christchurch Immunisation Coordination Committee.
    Ford RP; Bell DW; Slade B; McCormack SP
    N Z Med J; 1998 Aug; 111(1071):301. PubMed ID: 9760956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving the second dose of measles-mumps-rubella vaccine to school entry: implications for control of rubella.
    Heath TC; Burgess MA; Forrest JM
    Commun Dis Intell; 1998 Aug; 22(8):157-8. PubMed ID: 9735550
    [No Abstract]   [Full Text] [Related]  

  • 20. Are vaccination rates higher if providers receive free vaccines and follow contraindication guidelines?
    Zimmerman RK; Mieczkowski TA; Michel M
    Fam Med; 1999 May; 31(5):317-23. PubMed ID: 10407708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.